详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions

95| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Xinmin Street 71#, Changchun 130021, China [2]Present Address: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China [3]Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden

出处：

DOI：

ISSN：

关键词： PD-1 PD-L1 Multiple sclerosis Experimental autoimmune encephalomyelitis Immune tolerance

摘要：

Multiple sclerosis (MS) is an autoimmunity-related chronic demyelination disease of the central nervous system (CNS), causing young disability. Currently, highly specific immunotherapies for MS are still lacking. Programmed cell death 1 (PD-1) is an immunosuppressive co-stimulatory molecule, which is expressed on activated T lymphocytes, B lymphocytes, natural killer cells, and other immune cells. PD-L1, the ligand of PD-1, is expressed on T lymphocytes, B lymphocytes, dendritic cells, and macrophages. PD-1/PD-L1 delivers negative regulatory signals to immune cells, maintaining immune tolerance and inhibiting autoimmunity. This review comprehensively summarizes current insights into the role of PD-1/PD-L1 signaling in MS and its animal model experimental autoimmune encephalomyelitis (EAE). The potentiality of PD-1/PD-L1 as biomarkers or therapeutic targets for MS will also be discussed.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区医学

小类 | 2 区神经科学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区神经科学

JCR分区：

出版当年[2019]版：

Q1 NEUROSCIENCES

最新[2023]版：

Q1 NEUROSCIENCES

影响因子： 4.6 最新[2023版] 4.7 最新五年平均 4.5 出版当年[2019版] 4.519 出版当年五年平均 4.586 出版前一年[2018版] 5.59 出版后一年[2020版]

第一作者：

第一作者机构： [1]Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Xinmin Street 71#, Changchun 130021, China [2]Present Address: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective [2]PD-1/PD-L1 Interaction Maintains Allogeneic Immune Tolerance Induced by Administration of Ultraviolet B-Irradiated Immature Dendritic Cells [3]PD-1/PD-L1 Interaction Maintains Allogeneic Immune Tolerance Induced by Administration of Ultraviolet B-Irradiated Immature Dendritic Cells [4]N6-methyladenosine participates in mouse hippocampus neurodegeneration via PD-1/PD-L1 pathway [5]Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors [6]Proteome Profiling of Experimental Autoimmune Encephalomyelitis Mouse Model and the Effect of a SUMO E1 Inhibitor [7]Bushen Yisui Capsule ameliorates axonal injury in experimental autoimmune encephalomyelitis [8]Effect of Cordyceps sinensis on the Treatment of Experimental Autoimmune Encephalomyelitis: A Pilot Study on Mice Model [9]Epimedium flavonoids ameliorate experimental autoimmune encephalomyelitis in rats by modulating neuroinflammatory and neurotrophic responses [10]Zuogui pills for myelinolysis in a rat model of experimental autoimmune encephalomyelitis